These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

304 related items for PubMed ID: 11769472

  • 1. [Prostate specific antigen: a role of PSA in the diagnosis of prostate cancer].
    Nutahara K, Higashihara E.
    Rinsho Byori; 2001 Oct; 49(10):963-6. PubMed ID: 11769472
    [Abstract] [Full Text] [Related]

  • 2. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
    Haese A, Dworschack RT, Partin AW.
    J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
    [Abstract] [Full Text] [Related]

  • 3. [Prostate-specific antigen and its related parameters in detecting prostate cancer].
    Kuruma H, Egawa S.
    Gan To Kagaku Ryoho; 2003 Jan; 30(1):11-5. PubMed ID: 12557698
    [Abstract] [Full Text] [Related]

  • 4. [Prostate cancer].
    Uchida K, Akaza H.
    Gan To Kagaku Ryoho; 2001 Oct; 28(10):1469-74. PubMed ID: 11681260
    [Abstract] [Full Text] [Related]

  • 5. Advances in the application of prostate-specific antigen in the detection of early-stage prostate cancer.
    Kamoi K, Babaian RJ.
    Semin Oncol; 1999 Apr; 26(2):140-9. PubMed ID: 10597725
    [Abstract] [Full Text] [Related]

  • 6. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
    Raaijmakers R, Wildhagen MF, Ito K, Pàez A, de Vries SH, Roobol MJ, Schröder FH.
    Urology; 2004 Feb; 63(2):316-20. PubMed ID: 14972481
    [Abstract] [Full Text] [Related]

  • 7. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
    Roobol MJ, Kranse R, de Koning HJ, Schröder FH.
    Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
    [Abstract] [Full Text] [Related]

  • 8. [Advancements in PSA-based screening for prostate cancer].
    Ito K.
    Rinsho Byori; 2004 Jul; 52(7):611-7. PubMed ID: 15344561
    [Abstract] [Full Text] [Related]

  • 9. Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial.
    Määttänen L, Hakama M, Tammela TL, Ruutu M, Ala-Opas M, Juusela H, Martikainen P, Stenman UH, Auvinen A.
    Br J Cancer; 2007 Jan 15; 96(1):56-60. PubMed ID: 17213825
    [Abstract] [Full Text] [Related]

  • 10. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
    Jegu J, Tretarre B, Grosclaude P, Rebillard X, Bataille V, Malavaud B, Iborra F, Salama G, Rischmann P, Villers A.
    Prog Urol; 2009 Jul 15; 19(7):487-98. PubMed ID: 19559380
    [Abstract] [Full Text] [Related]

  • 11. Prostate cancer and prostate-specific antigen (PSA) screening in Austria.
    Vutuc C, Schernhammer ES, Haidinger G, Waldhör T.
    Wien Klin Wochenschr; 2005 Jul 15; 117(13-14):457-61. PubMed ID: 16091872
    [Abstract] [Full Text] [Related]

  • 12. Prostate specific-antigen distribution in asymptomatic Canadian men with no clinical evidence of prostate cancer.
    Chun FK, Perrotte P, Briganti A, Benayoun S, Lebeau T, Ramirez A, Lewinshtein DJ, Valiquette L, Guay JP, Karakiewicz PI.
    BJU Int; 2006 Jul 15; 98(1):50-3. PubMed ID: 16831142
    [Abstract] [Full Text] [Related]

  • 13. The value of prostatic specific antigen in prostate cancer screening in the community.
    Jubelirer SJ, Tierney JP, Oliver S, Serrato JM, Farra S, Plymale J, Hodge E.
    W V Med J; 1994 Apr 15; 90(4):140-2. PubMed ID: 7516602
    [Abstract] [Full Text] [Related]

  • 14. Screening for prostate cancer in U.S. men ACPM position statement on preventive practice.
    Lim LS, Sherin K, ACPM Prevention Practice Committee.
    Am J Prev Med; 2008 Feb 15; 34(2):164-70. PubMed ID: 18201648
    [Abstract] [Full Text] [Related]

  • 15. Repeating an abnormal prostate-specific antigen (PSA) level: how relevant is a decrease in PSA?
    Connolly D, Black A, Murray LJ, Nambirajan T, Keane PF, Gavin A.
    Prostate Cancer Prostatic Dis; 2009 Feb 15; 12(1):47-51. PubMed ID: 18762815
    [Abstract] [Full Text] [Related]

  • 16. [Mass screening for prostate cancer is the best approach to early diagnosis and treatment of prostate cancer].
    Zhao XJ, Kong XB, Wang WH.
    Zhonghua Nan Ke Xue; 2003 Nov 15; 9(8):563-5, 568. PubMed ID: 14689882
    [Abstract] [Full Text] [Related]

  • 17. Prostate cancer: a review of common underwriting problems, Part 1.
    Richie RC, Swanson JO.
    J Insur Med; 2004 Nov 15; 36(3):242-54. PubMed ID: 15495440
    [Abstract] [Full Text] [Related]

  • 18. Percent free PSA as an additional measure in a prostate cancer screen.
    Miele ME.
    Clin Lab Sci; 2001 Nov 15; 14(2):102-7. PubMed ID: 15625982
    [Abstract] [Full Text] [Related]

  • 19. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal.
    Welch HG, Schwartz LM, Woloshin S.
    J Natl Cancer Inst; 2005 Aug 03; 97(15):1132-7. PubMed ID: 16077071
    [Abstract] [Full Text] [Related]

  • 20. Prevalence of prostate cancer in aging males receiving PSA (prostate specific antigen) screening test (A campaign for celebration of Siriraj Established Day).
    Srinualnad S, Charoenkraikamol C, Toraksa S, Uiprasertkul M, Amornvesukit T, Taweemonkongsap T, Udompunturak S, Nualyong C, Tantiwong A.
    J Med Assoc Thai; 2006 Jan 03; 89(1):37-42. PubMed ID: 16583579
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.